Trial Profile
A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Ficlatuzumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 10 Aug 2020 According to an Aveo Oncology financial media release, data from this study was presented at the in the journal Cancers.
- 16 Apr 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.